ofatumumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4951	679818-59-8

Description:

Molecule	Description
Synonyms: ofatumumab arzerra GSK1841157 HuMax-CD20 2F2	Ofatumumab is a human monoclonal antibody (IgG1) that binds specifically to a distinct epitope encompassing both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage and on B cell tumours. The binding of ofatumumab to the membrane-proximal epitope of the CD20 molecule induces recruitment and activation of the complement pathway at the cell surface, leading to complement dependent cytotoxicity and resultant lysis of tumour cells. Ofatumumab has been shown to induce appreciable lysis of cells with high expression levels of complement defence molecules. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

ofatumumab
arzerra
GSK1841157
HuMax-CD20
2F2

Ofatumumab is a human monoclonal antibody (IgG1) that binds specifically to a distinct epitope encompassing both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage and on B cell tumours. The binding of ofatumumab to the membrane-proximal epitope of the CD20 molecule induces recruitment and activation of the complement pathway at the cell surface, leading to complement dependent cytotoxicity and resultant lysis of tumour cells. Ofatumumab has been shown to induce appreciable lysis of cells with high expression levels of complement defence molecules.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.67	mg	P

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
April 19, 2010	EMA	Novartis Europharm Ltd
March 23, 2021	PMDA	Novartis Pharma K.K.
Oct. 26, 2009	FDA	GLAXO GRP LTD

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chills	200.62	22.59	124	5415	113254	63370229
Influenza like illness	168.31	22.59	92	5447	66732	63416751
Multiple sclerosis relapse	154.07	22.59	78	5461	48400	63435083
Pyrexia	150.51	22.59	194	5345	470284	63013199
Accidental exposure to product	139.29	22.59	61	5478	27344	63456139
Febrile neutropenia	113.53	22.59	89	5450	118360	63365123
COVID-19	93.55	22.59	78	5461	113025	63370458
Device malfunction	88.27	22.59	39	5500	17818	63465665
Incorrect dose administered by device	84.35	22.59	26	5513	4322	63479161
Headache	67.48	22.59	161	5378	633080	62850403

Showing 1 to 10 of 26 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	177.89	24.55	136	3786	136713	34816296
Pneumonia	137.03	24.55	184	3738	362443	34590566
Pyrexia	110.56	24.55	159	3763	332854	34620155
Neutropenic sepsis	101.80	24.55	43	3879	13724	34939285
Chills	66.47	24.55	62	3860	80981	34872028
Influenza like illness	65.57	24.55	40	3882	27594	34925415
Second primary malignancy	46.44	24.55	21	3901	7865	34945144
Infusion related reaction	44.23	24.55	41	3881	53016	34899993
Disease progression	43.60	24.55	57	3865	108020	34844989
Tumour lysis syndrome	41.23	24.55	25	3897	17034	34935975

Showing 1 to 10 of 17 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	218.73	22.32	166	6209	230833	79507180
Pyrexia	200.26	22.32	257	6118	678452	79059561
Chills	175.87	22.32	126	6249	160108	79577905
Pneumonia	171.39	22.32	235	6140	660011	79078002
Influenza like illness	129.15	22.32	77	6298	71630	79666383
Neutropenic sepsis	115.69	22.32	52	6323	27012	79711001
Multiple sclerosis relapse	76.08	22.32	47	6328	46486	79691527
Progressive multifocal leukoencephalopathy	67.65	22.32	33	6342	20567	79717446
COVID-19	64.60	22.32	71	6304	157603	79580410
Second primary malignancy	59.48	22.32	27	6348	14323	79723690

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01FA02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD20 (Clusters of Differentiation 20) inhibitors
ATC	L04AA52	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants
FDA EPC	N0000175657	CD20-directed Cytolytic Antibody
FDA MoA	N0000175078	CD20-directed Antibody Interactions
MeSH PA	D000970	Antineoplastic Agents

Showing 1 to 5 of 5 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Chronic lymphoid leukemia, disease	indication	92814006
Relapsing multiple sclerosis	indication	230372003
Secondary progressive multiple sclerosis	indication	425500002	DOID:0050783

Showing 1 to 3 of 3 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
B-lymphocyte antigen CD20	Surface antigen	P11836	CD20_HUMAN	ANTIBODY BINDING	Kd	9.92		IUPHAR	DRUG LABEL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
013301	NDDF
168892	MMSL
26825	MMSL
4029460	VUID
4029460	VANDF
444607009	SNOMEDCT_US
444609007	SNOMEDCT_US
6778	IUPHAR_LIGAND_ID
712566	RXNORM
8254	PUBCHEM_CID

Showing 1 to 10 of 20 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ARZERRA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0669	INJECTION, SOLUTION	20 mg	INTRAVENOUS	BLA	26 sections
ARZERRA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0669	INJECTION, SOLUTION	20 mg	INTRAVENOUS	BLA	26 sections
ARZERRA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0669	INJECTION, SOLUTION	20 mg	INTRAVENOUS	BLA	26 sections
ARZERRA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0690	INJECTION, SOLUTION	20 mg	INTRAVENOUS	BLA	26 sections
ARZERRA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0690	INJECTION, SOLUTION	20 mg	INTRAVENOUS	BLA	26 sections
ARZERRA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0690	INJECTION, SOLUTION	20 mg	INTRAVENOUS	BLA	26 sections
KESIMPTA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-1007	INJECTION, SOLUTION	20 mg	SUBCUTANEOUS	BLA	30 sections
KESIMPTA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-1007	INJECTION, SOLUTION	20 mg	SUBCUTANEOUS	BLA	30 sections
KESIMPTA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-1007	INJECTION, SOLUTION	20 mg	SUBCUTANEOUS	BLA	30 sections
KESIMPTA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-1007	INJECTION, SOLUTION	20 mg	SUBCUTANEOUS	BLA	30 sections

Showing 1 to 10 of 10 entries

Previous1Next